A panel of experts in the field of lower-risk myelodysplastic syndrome discusses current treatment paradigms, reviews clinical trial data, and provides insight on the evolving treatment landscape.
EP. 2: Clinical Insights into the COMMANDS Trial
September 21st 2023The expert panel reviews updated data from the COMMANDS trial on luspatercept in patients with lower-risk MDS and discusses their effect on clinical practice. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.
EP. 3: Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?
September 28th 2023Comprehensive insights on the differences and similarities in treatment algorithms for physicians treating patients with MDS in and outside the United States. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.
EP. 8: Treatment Strategies and Sequencing in MDS
October 12th 2023Rami Komrokji, MD, provides clinical insights on treatment decision-making, sequencing, and combinations for patients with myelodysplastic syndrome. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.